Recommendations-Union Budget FY27, Vyome Holdings, Inc.

“In the Union Budget 2026, India must place life sciences, biotech, and biopharma innovation at the core of our bioeconomy. I propose a dedicated Life Sciences & Biotech Innovation Mission with an allocation of ₹50,000+ crore focused purely on R&D incentives, translational research, clinical development, and global regulatory readiness—with clear, measurable targets on new molecular entities, biologics, vaccines, CGT platforms, IP generation, and global approvals and licensing.

We should also pilot a Life Sciences Sovereign Innovation Zone—a special economic region designed for novel pharma, biotech, CROs/CDMOs, and deep-tech healthcare startups, with globally competitive capital and operating frameworks, including streamlined financial and tax structures to attract global capital, and a diaspora- and talent-friendly visa program to bring back Indian professionals and welcome overseas experts. This zone should actively invite global universities and research institutions to co-build a preventing, curing, and scaling ecosystem—so India becomes not only the pharmacy of the world, but also a leading innovation engine for global healthcare.” Venkat Nelabhotla, Co-Founder, President, and CEO of Vyome Holdings, Inc.

MB Bureau